Alaunos Therapeutics, Inc. announced that it has been accepted to present a proffered talk at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) being held in New York, NY from September 28 October 1, 2022. Details of the presentation are as follows: Title: Objective clinical response by KRAS mutation-specific TCR-T cell therapy in previously treated advanced Non-small cell lung cancer; Presenter: Marcelo V. Negrao, MD, Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center; Date and Time:Friday, September 30, 2022, 8:30am ET; Session Title: Session 6: Cellular Therapies: Engineering T cells.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1 USD | +2.04% |
|
-2.91% | -5.70% |
06-10 | BioSig Technologies Appoints Ferdinand Groenewald as Interim CFO | MT |
05-15 | Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-5.70% | 15.69M | |
+16.76% | 123B | |
+15.92% | 111B | |
-7.18% | 23.63B | |
+4.37% | 22.58B | |
-37.63% | 17.61B | |
-8.16% | 17.6B | |
-14.90% | 17.26B | |
+2.40% | 13.55B | |
+28.81% | 11.34B |
- Stock Market
- Equities
- TCRT Stock
- News Alaunos Therapeutics, Inc.
- Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference